Impact of statin treatment on cardiovascular risk in patients with type 1 diabetes: a population-based cohort study

Table 3 Factors associated with occurrence of the primary outcome

Variable	Univariable HR [95% CI]	P value	Adjusted HR [95% CI]^a	P value
Sex, male	1.16 [1.01–1.32]	0.035	1.38 [1.20–1.58]	< 0.001
Age, years	1.05 [1.05–1.06]	< 0.001	1.05 [1.04–1.05]	< 0.001
Insurance type
Health insurance	1 (Ref)	–	1 (Ref)	–
Medical aid	1.35 [1.08–1.69]	0.009	1.35 [1.07–1.70]	0.010
Comorbidities
Hypertension	2.04 [1.79–2.32]	< 0.001	1.26 [1.08–1.48]	0.004
Renal disease	1.32 [1.10–1.59]	0.003	1.18 [0.98–1.43]	0.080
Medication
Antiplatelet	1.81 [1.59–2.07]	< 0.001	1.32 [1.14–1.53]	< 0.001
RAAS inhibitor	1.36 [1.19–1.56]	< 0.001	0.89 [0.76–1.04]	0.131
Statin	0.96 [0.83–1.10]	0.531	0.76 [0.66–0.88]	< 0.001

Data were obtained from a multivariable time-dependent Cox proportional hazard regression model
CI confidence interval, HR hazard ratio, RAAS renin–angiotensin–aldosterone system
^aAdjusted for sex, age, insurance type, hypertension, renal disease, and medications

ISSN: 1479-5876